about
Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive ToolsPrimary progressive multiple sclerosis: current therapeutic strategies and future perspectivesSlow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imagingFlow cytometric analysis reveals the high levels of platelet activation parameters in circulation of multiple sclerosis patients.Multiple sclerosis: Pathology, diagnosis and treatments.Therapeutic Advances and Future Prospects in Progressive Forms of Multiple SclerosisSpring cleaning: time to rethink imaging research lines in MS?Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question.Clinical Presentations and Phenotypic Spectrum of Multiple Sclerosis at a University Hospital in Saudi Arabia.
P2860
Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosisMicroglia pre-activation and neurodegeneration precipitate neuroinflammation without exacerbating tissue injury in experimental autoimmune encephalomyelitisMonitoring Progressive Multiple Sclerosis with Novel Imaging TechniquesThe monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosisCell-free mitochondrial DNA in progressive multiple sclerosisThe Multiple Sclerosis Severity Score: fluctuations and prognostic ability in a longitudinal cohort of patients with MSGlial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?Evolution of clinical trials in multiple sclerosisMechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple SclerosisMultiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multipl
P921
Q26795786-9A147AAC-32FD-4EB7-BF73-102CF04BED32Q29030703-452AA1D7-CBC9-4A2B-99F2-36804528E03FQ31140002-B3AA7DC7-C3E0-4445-98F9-30BC27257342Q33705173-64C7D437-1687-4022-A90B-EE12AF156376Q33745006-F1A67544-AE44-42B3-A699-C76BFAEAA9B8Q36484443-FD3D0049-E65A-4C8D-BF35-0340522D0DA3Q38737202-32367386-19A5-47CC-A605-F50F74D381F2Q38815391-CEF897F6-3FD5-499B-97E0-34AD72293E3BQ48307050-8FBD6D56-C642-4F6D-B837-B05326258C3CQ55439494-6B29A9F2-83D0-4243-9DE5-4C32996AE145
P2860
Q61642969-40AC7B87-C0C7-40CA-A4C7-C307BABEB690Q61804674-595C1646-E034-4A8E-8597-1C39B033E335Q62202342-E45B5928-1CEF-4931-95D3-6998FB12571EQ64055117-8C99B817-1CC7-4C80-8AEF-2EF62AE8A51AQ64076159-AC518116-73E1-47AB-98ED-1EF8D102B356Q64081658-DF68F508-B585-4A29-9A04-DF5D28C200A0Q64118591-5DBC73C8-FC6D-4DA6-A2E1-93B5B9D7AE0FQ64122269-4B92CAE8-DD4C-4BDD-87E8-A7E6A0DFE848Q64229784-29FAD37F-7239-4A4D-802D-CB9B75B78584Q64450175-C18D3F46-B0F3-4A4D-916C-5B6286701DEC
P921
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Progressive multiple sclerosis
@ast
Progressive multiple sclerosis
@en
Progressive multiple sclerosis
@nl
type
label
Progressive multiple sclerosis
@ast
Progressive multiple sclerosis
@en
Progressive multiple sclerosis
@nl
prefLabel
Progressive multiple sclerosis
@ast
Progressive multiple sclerosis
@en
Progressive multiple sclerosis
@nl
P2860
P1476
Progressive multiple sclerosis
@en
P2093
Robert J Fox
P2860
P304
P3417
Progressive-Multiple-Sclerosis
P356
10.1097/WCO.0000000000000195
P407
P577
2015-06-01T00:00:00Z